Kidney Stone Prevention Programme

The Litholink programme has been a leader in the use of 24-hour urine chemistries in the metabolic evaluation of kidney stone patients for 20 years. Litholink was founded by Drs Fredric Coe and John Asplin to bring their knowledge and expertise to a wider audience. A focus on superior service ensures that clients receive patient results in a unique graph and table format, accompanied by expert interpretation of the laboratory results. 

Benefits of the programme

  • Ease of use
  • Research
  • Cost effective
  • Ease of use for doctors and patients

    Patient specific interpretation and recommendations from leading urologists saves Consultant’s time The system allows for tracking patient over time and consideration of past results when interpreting current samples.

    Inclusion of the patient’s current medical treatments in the interpretation of laboratory results.

    24-hour urine collected using antimicrobial preservative and at room temperature to maximize sample integrity Urine supersaturations calculated for common stone forming salts.

    Urine collection kits designed to allow the patient to do the urine collection at home and ship the sample directly to Litholink without having to return to a laboratory facility or doctor’s office.

    Specialized pediatric report comparing results to age- and gender-matched children.

    Specialized testing system available for patients with cystinuria, which includes a direct measurement of cystine supersaturation.

  • Active research programme

    Litholink is committed to remaining at the forefront of laboratory testing for patients with urolithiasis through continuous development in scientific research, assay development, and updating our interpretive software as the diagnosis and treatment of patients with urolithiasis evolves. Litholink collaborates with leading researchers in order to advance the field of urolithiasis research.

    Over the past 20 years, Litholink has contributed to over 80 published peer-reviewed studies.

  • 83% reduction in the rate of stone formation

    The University of Chicago Kidney Stone Clinic, including at that time, Litholink founders Coe and Asplin, conducted a study of the cost benefits of testing and treating kidney stone formers. The study, published in Kidney International in 1996, was based on 1,092 stone formers treated at the clinic.

    Treatment caused an 83% reduction in the rate of stone formation and the study estimated the savings in this population were above $2,000 per patient per year, net of treatment and pharmacy costs.¹

    Several studies have reported results that confirm the efficacy and transferability of the type of techniques used by Drs Asplin and Coe. See, for example, the following:
    Lingeman, et al. Medical reduction of stone risk. J Urology. 1998;160:1629-1634.
    Coe et al. Differences in urine volume and supersaturation. J Urology. 2001; 166:423-428
    Mardis et. al. Outcome of metabolic evaluation. J Urology. 2004;171:85

    1. Parks JH, Coe FL, The Financial Effects of Kidney Stone Prevention. Kidney International. 1996 Nov;50(5):1706-12

What do physicians think about our service?

By tracking the patient and physicians results and suggesting corrections, by being available for consultation for treatment programs that are not working, Litholink reduced recurrent stones, hospitalizations and operations.

The enrollment process is simple and straightforward. The reporting is clear and concise. My practice is more efficient than ever before

Our test reports


Current Test Overview & Medical Director’s Notes

Features a listing of new samples processed for this report and the turnaround time.

Provides specific quality control notes from the Medical Director, where appropriate.


Summary Stone risk factors

Features a patient and clinician-friendly graphical display of primary stone risk factors.

Colours and font-bolding highlight values with increased risk for stone formation.

Interpretive paragraphs offer therapeutic suggestions.


Stone Risk Factors, Dietary Factors & Normalized Renal Function Results

Provides saturation values for stone-forming salts.

As with Summary Stone Risk Factors, colour and font-bolding represent increased risk for stone formation.

All data is time sequential, clearly showing response to therapy.


Clinical Report

A quick-read summary of kidney stone related medical history as provided by patient.

Allows for easy confirmation of medication usage and alterations in diet following evaluation.


Cystine Results

Cystine report provides direct measurement of cystine saturation.

Cystine report is valid in the presence of sulfhydral-based medications.


Single Day Report

Single Day Report provides a condensed version of our Patient Results Report.

Features a patient and clinician-friendly graphical display of primary stone risk factors.

Colours and font-bolding highlight values with increased risk for stone formation.

Interpretive paragraphs offer therapeutic suggestions.

Patient education leaflets









Fourier Tansform InfraRed Spectroscopy of Kidney Stones.

FT-IR spectroscopy is becoming the gold standard for (physical) kidney stone analysis.

Research undertaken in Italy and published in April 2014 concluded that "FT-IR spectroscopy leads to unambiguous information about the stone composition, both for main substances and trace elements, all essentials to guide therapy."

Once a person has a kidney stone, the risk of forming another stone is high. A combination of FT-IR analysis of the stone itself and the Litholink programme provides the physician with a comprehensive set of results aimed to help prevent kidney stones from ever reoccurring. This offers benefits both to the patient in terms of less pain, inconvenience and lost working days and to the health provider in terms of a reduction in emergency medical costs.

Cellmark is able to offer FT-IR analysis of kidneys stones at our UK laboratories - call our Customer Services team on 0800 036 2522.